cases depending upon the type of cancer and the demographic region. Oral and Oropharyngeal cancers are the most common forms of cancer in India. In this study we evaluate to anlayze if there is any relation between hsCRP in Head & Neck cancer patients compared to age matched controls.
Objective of the study. To compare the serum hs-CRP levels in subjects with Head & Neck cancer and normal healthy subjects. To assess if there is any correlation between primary tumour size and serum hsCRP levels.
Materials and methods. This prospective cross sectional case control study was conducted as per ICH GCP guideline and Ethics committee approval. Informed consent was obtained prior to the study. The study subjects consisted of age and sex matched, Study Group (Cases): 36 subjects with proved Head & Neck cancer and Control Group (Controls): 36 normal healthy volunteer subjects.
Sample Size selection: In the absence of any literature providing hs CRP levels in the Head & Neck cancer, values of colorectal cancer has been employed for estimating the sample size. Erlinger et al [8] , indicated that the mean CRP levels amongst cases of colorectal cancer and matched normal control subjects were around 2.44 and 1.94 respectively. In order to detect statistically significant difference in the mean hsCRP levels between the two groups, it was estimated that at least 36 subjects in each group need to be included.
Inclusion criteria: Age group: 18 to 80 years (Both sexes), In the Study group: newly diagnosed Oral and Oropharyngeal cancer confirmed by biopsy, Evaluated clinically by CT Scan. Leucocytes count within normal range. Exclusion criteria was: Subjects with inflammatory diseases, Subjects with Infections in the recent past (< 3mth), Subjects with tissue injury in the recent past (<6 mth, Subject on Corticosteroids, Statins, NSAIDS, Potassium humate. Subjects were enrolled as per the inclusion and exclusion criteria.
A complete general physical examination was performed. Subjects with Head & Neck cancer, the primary site, the size of the primary tumour & neck nodes was evaluated using clinically & with CT scan. Subjects were staged using UICC TNM staging system. Blood samples were taken for analysis of complete hemogram and hsCRP in all the study subjects (both cases and controls). Collection of blood samples: 4 ml blood was collected from both cases and controls and was allowed to clot. The samples were then centrifuged and serum was separated using a micropipette and stored at -20 °C. Lab analysis: hsCRP values were determined using Quantitative Immunoturbidimetric method. The procedure was carried out at a wavelength of 540 nm and at a temperature of 37 °C with a Cuvette length of 1 cm on fresh serum samples using a spectrometer. Absorbances A1 and A2 were taken at times t = 0 and t = 4 minutes and compared with the known calibrator values. For readings with absorbance greater than 3.5, tests were conducted after diluting the samples by 1:2 or 1:5 with normal saline (0.9 % NaCl Solution). Statistical analysis was carried out on all the quantitative data such as serum hs CRP, age, tumour size, etc.
Statistical analysis: All the quantitative data, such as hsCRP, age, tumour size, etc., were summarized in terms of mean and median. Standard deviation was calculated as a measure of variation. Differences in the mean serum hsCRP between cancer cases and controls were tested through student's T test/ appropriate non parametric tests. Relationship between the size of the tumour and hsCRP was estimated through correlation analysis. The Correlation coefficient was tested through student's T test.
Results. Over a period of 6 months 72 subjects were recruited for the study. Number of Cases (Cancer subjects) was 36 and age and sex matched control were 36. All the subjects data were considered evaluable. Mean age of the Study subject was 59.55 yrs (SD + 9.9) and the control group 59.06 yrs (SD + 9.7). Male: Female was 3:1in study group compared to 2.2:1 in controls.
In the study group 22 (61.11 %) had Oral Cancers and 14 (38.89 %) had Cancer of the Oropharynx. Overall in the Stage was Tumour T2 (2-4 cms) = 8 Fig. 2 ]. In the Study subject with cancer the mean hsCRP levels with tumour size T2 was 19.362 ± 7.0104, T3 was 21.325 ± 23.2744, T4 was 18.350 ± 21.0915 and P value was 0.878. The mean hs C RP levels of individuals with Node size N0 was 20.3 ± 35.07, N1 was 13.8 ± 5.37, N2 was 21.6 ± 25.0 2, N3 was 12 .1 ± 1.7. A trend towards increasing hsCRP with increasing tumour size and nodal size was seen [ Fig. 3A & 3B] . Discussion. Erlinger et al [4] indicated that plasma CRP concentrations were higher among all colorectal cases combined than controls (median CRP, 2.44 vs 1.94 mg/L; P = 0.01). McSorley et al [9] indicated that C-reactive protein levels were significantly higher in the women who later developed ovarian cancer compared to normal individuals. The risk of developing ovarian cancer among women in the highest third of the distribution of CRP compared with those in the lowest third was 1.72 (95 % confidence interval 1.06-2.77), with evidence of an increasing risk with increasing concentration of CRP (P-trend = 0.02). Otake et al [10] indicated that inflammation is linked to the growth of colorectal adenomas. The multivariate-adjusted odds ratios of large adenomas for the lowest to highest categories of CRP were 1.00 (referent), 1.81 (95 % confidence interval 1.17-2.80), 1.61 (95 % confidence interval 1.03-2.52), and 2.21 (95 % confidence interval 1.28-3.84), respectively (P-trend = 0.01). Aleksandrova et al [11] indicated that elevated CRP concentrations are related to a higher risk of colon cancer, predominantly among men. Multivariable-adjusted relative risks for CRP concentrations of > or = 3.0 mg/L versus <1.0 mg/L were 1.36 (95 % confidence interval (CI): 1.00, 1.85; P-trend = 0.01) for colon cancer and 1.02 (95 % CI: 0.67, 1.57; P-trend = 0.65) for rectal cancer. Colon cancer risk was significantly increased in men (relative risk = 1.74, 95 % CI: 1.11, 2.73; P-trend = 0.01) but not in women (relative risk = 1.06, 95 % CI: 0.67, 1.68; P-trend = 0.13) [1] .
Fig. 3B. An increasing trend in hsCRP is seen as the Nodal Size increases).
Certain other studies have indicated that the serum hs CRP values are not elevated significantly in different types of cancer cases compared to controls. Zhang et al indicated that C-reactive protein levels are not associated with increased risk for colorectal cancer in women, and low grade inflammation was seen in the cases (P-trend = 0.09) [15] . Ito et al indicated that high serum CRP levels did not appear to increase the risk of colorectal cancer. The OR of the highest serum CRP levels was 1.18 (95 % CI: 0.68-2.06) for colorectal cancer and 1.42 (95 % CI: 0.73-2.74) for colon cancer, compared to subjects with lowest serum levels. The OR for incidence of colorectal cancer showed a similar trend, but the difference was not significant [8] . Erlinger et al [4] and Aleksandrova et al [1] have also indicated that serum hs CRP levels were not significantly elevated in rectal cancer cases compared to matched controls. In our study serum hsCRP levels were markedly elevated in the subjects with cancers against age and sex matched healthy subjects 3.039 ± 2.617 v/s 19.236 ± 19.003 respectively (P < 0.0001) [Fig. 3] .
Study by Erlinger et al [4] demonstrated that plasma CRP concentrations were higher among colorectal cancers subjects compared to controls (median CRP, 2.44 vs 1.94 mg/L; P = 0.01) [8] . McSorley et al [9] indicated that the risk of developing ovarian cancer among women in the highest third of the distribution of CRP compared with those in the lowest third was 1.72 (95 % confidence interval 1.06-2.77), with evidence of an increasing risk with increasing concentration of CRP (P-trend = 0.02) [9] .
From our study we infer that subjects with Oral and Oropharyngeal cancers had higher hsCRP levels than ovarian cancer subjects (literature data). The association of tumour inflammation and higher hsCRP levels is clearly demonstrated.
In another study carried out by Otake et al [10] indicated that the multivariate-adjusted odds ratios of large adenomas for the lowest to highest categories of CRP were 1.00 (referent), 1.81 (95 % confidence interval 1.17-2.80), 1.61 (95 % confidence interval 1.03-2.52), and 2.21 (95 % confidence interval 1.28-3.84), respectively (P-trend = 0.01) [10] .
The study carried out by Aleksandrova et al [1] indicated that the Multivariable-adjusted relative risks for CRP concentrations of > or = 3.0 mg/L versus <1.0 mg/L were 1.36 (95 % confidence interval (CI): 1.00, 1.85; P-trend = 0.01) for colon cancer and 1.02 (95 % CI: 0.67, 1.57; P-trend = 0.65) for rectal cancer. Colon cancer risk was significantly increased in men (relative risk = 1.74, 95 % CI: 1.11, 2.73; P-trend = 0.01) but not in women (relative risk = 1.06, 95 % CI: 0.67, 1.68; P-trend = 0.13) [1] .
hsCRP levels may not be markedly elevated in all types of cancers but they are significantly elevated in Oral and Oropharyngeal cancers. In our study serum hsCRP levels did not increase significantly with increase in tumour or neck node size. Mean serum hsCRP levels in tumour size T2 was 19.362 ± 7.0104, T3 was 21.325 ± 23.2744, T4 was 18.350 ± 21.0915 and P value was 0.878.
Therefore, hsCRP levels in the serum may not relate to locoregional cancers burden. The probable explanation for this is the etiologic association of Human papillomavirus (HPV) infection in many oral and oropharyngeal squamous cell carcinoma [6, 12] . The number of cancer cases is increasing day by day. According to some studies anti-inflammatory drugs decrease the risk of developing cancer [3] . Therefore; further studies need to be done, to evaluate the role of hsCRP as a biomarker for cancer, screening and risk evaluation.
Conclusions. Inflammatory responses play decisive roles at different stages of tumour development, initiation, promotion, malignant conversion, invasion, and metastasis. This study shows serum hsCRP levels were significantly elevated in Head & neck cancer cases compared to age matched normal control subjects. hsCRP Can be used as a surrogate marker of oral & Oropharyngeal cancer. Measuring and charting hsCRP values can prove useful in determining disease progress or the effectiveness of treatments. Further studies are contemplated.
